Table 2. Grading of the immune-staining for Grp94.
| Patients | negative (−) | moderate (1 +) | strong (2 +) |
|---|---|---|---|
| Total (27) | 1 | 4 | 22 |
| Males/Females | 0/1 | 2/2 | 10/11 |
| Tumor staging | |||
| I/II | 1 | 2 | 7 |
| III/IV | 0 | 2 | 15 |
| Tumor grading | |||
| G2 | 1 | 1 | 12 |
| G3 | − | 3 | 10 |
Scores for the intensity of the immunostaining for Grp94 was assessed by three independent observers who analyzed slices of the tumor sections on different occasions, as specified in Methods. Final score was assigned after the general agreement on the evaluation of any single sample. Only one negative score (female patient, CRC, stage I/II) was assigned in 27 samples. Thus, a statistically higher proportion of patients showed positivity for Grp94 (p = 4.172 × 10−7, exact binomial test). More tumors at later stages (p = 0.0074, exact binomial test) but not at higher grade (p = 0.34) stained strongly for Grp94. The Grp94 expression was neither associated with tumor stage (p = 0.39, Fisher's exact test) nor with tumor grading (p = 0.45).